Δευτέρα 28 Νοεμβρίου 2016

Does radiotherapy still have a role in unresected biliary tract cancer?

Abstract

The benefits of radiotherapy for inoperable biliary tract cancer remain unclear due to the lack of randomized data. We evaluated the impact of radiotherapy on survival in elderly patients using the SEER-Medicare database. Patients in the SEER-Medicare database with inoperable biliary tract tumors diagnosed between 1998 and 2011 were included. We used multivariate logistic regression to evaluate factors associated with treatment selection, and multivariate Cox regression and propensity score matching to evaluate treatment selection in relation to subsequent survival. Of the 2343 patients included, 451 (19%) received radiotherapy within 4 months of diagnosis. The use of radiotherapy declined over time, and was influenced by receipt of chemotherapy and patient age, race, marital status, poverty status, and tumor stage and type. Median survival was 9.3 (95% CI 8.7–9.7) months among patients who did not receive radiation and 10.0 (95% CI 9.1–11.3) months among those who received radiation, conditional on having survived 4 months. In patients who received chemotherapy (n = 1053), receipt of radiation was associated with improved survival, with an adjusted hazard ratio of 0.82 (95% 0.70–0.97, P = 0.02). In patients who did not receive chemotherapy (n = 1290), receipt of radiation was not associated with improved survival, with an adjusted hazard ratio of 1.09 (95% 0.91–1.30, P = 0.34). Propensity-scored matched analyses showed similar results. Despite the survival benefit associated with the addition of radiotherapy to chemotherapy, the use of radiation for unresectable biliary tract cancers has declined over time.

Thumbnail image of graphical abstract

The benefits of radiotherapy for elderly patients with inoperable biliary tract cancer remain unclear due to the lack of randomized data given the rarity of this cancer. Using the SEER-Medicare database, we found that the use of radiotherapy has declined over time, and is influenced by tumor, patient, and socioeconomic factors, and that any survival benefit with radiotherapy is confined to those patients who received concurrent chemotherapy.



from Cancer via ola Kala on Inoreader http://ift.tt/2gn4m1C
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου